IMM-1-104 (implied lead)
Advanced solid tumors with MAPK pathway mutations (e.g., KRAS, NRAS, BRAF)
Phase 1/2aActive
Key Facts
Indication
Advanced solid tumors with MAPK pathway mutations (e.g., KRAS, NRAS, BRAF)
Phase
Phase 1/2a
Status
Active
Company
About Immuneering
Immuneering is developing a new class of cancer medicines called Deep Cyclic Inhibitors, which employ a pulsed dosing strategy to overcome the limitations of traditional continuous inhibition. The company's lead programs target the MAPK pathway, a critical driver in many cancers, with the goal of delivering more durable responses and better tolerability. Immuneering is a publicly traded company (NASDAQ: IMRX) with a seasoned leadership team and a clear focus on transforming cancer care through innovative treatment paradigms.
View full company profile